31 results
8-K
EX-99.3
CLNN
Clene Inc
21 Dec 23
Regulation FD Disclosure
7:00am
a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene
8-K
EX-99.2
CLNN
Clene Inc
8 Jan 24
Regulation FD Disclosure
7:07am
is an investigational first-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets
8-K
EX-99.2
CLNN
Clene Inc
29 Feb 24
Regulation FD Disclosure
8:05am
and function via a mechanism that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered
8-K
EX-99.3
CLNN
Clene Inc
16 Apr 24
Regulation FD Disclosure
4:06pm
that targets mitochondrial function and the NAD pathway while reducing oxidative stress. CNM-Au8® is a federally registered trademark of Clene
8-K
EX-99.2
CLNN
Clene Inc
22 Feb 24
Regulation FD Disclosure
8:04am
-in-class therapy that improves central nervous system cells’ survival and function via a mechanism that targets mitochondrial function and the NAD pathway
8-K
EX-99.1
40cur cg8
7 Nov 23
Clene Reports Third Quarter 2023 Financial Results and Operating Highlights
8:02am
8-K
EX-99.2
ny69cn1dld2bu4
21 Dec 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
onej ib1ljkewz
8 May 24
CLENE REPORTS First QUARTER 2024 FINANCIAL RESULTS AND RECENT OPERATING HIGHLIGHTS
8:01am
8-K
EX-99.1
rfl1okw40qpt
13 Mar 24
Clene Reports Full Year 2023 Financial Results
8:02am
424B3
p70nna 55r
18 Dec 20
Prospectus supplement
2:24pm
S-4
v1awndznxrnptgf2k
10 Sep 20
Registration of securities issued in business combination transactions
8:51am
424B3
c5lfvagniasdvqg5r
21 Apr 21
Prospectus supplement
6:04am
424B3
z28cy
2 Aug 21
Prospectus supplement
5:03pm
S-1
0pdijm3870 ko7sv
17 Feb 21
IPO registration
12:00am
10-K
yraoj3g8 hwfkjihegp
29 Mar 21
Annual report
12:00am